PARP Inhibitors in Prostate Cancer: A Promise Delivered

被引：2
|
作者：
Tripathi, Abhishek [1 ]
McFarland, Taylor [2 ]
Agarwal, Neeraj [2 ]
机构：
[1] Univ Oklahoma, Hlth Sci Ctr, Stephenson Canc Ctr, Oklahoma City, OK USA
[2] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
来源：
EUROPEAN UROLOGY ONCOLOGY | 2020年 / 3卷 / 05期
关键词：
MUTATIONS;
D O I：
10.1016/j.euo.2020.08.006
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：612 / 614
页数：3
相关论文
共 50 条
  • [31] Cancer Cells Haploinsufficient for ATM Are Sensitized to PARP Inhibitors by MET Inhibition
    D'Ambrosio, Concetta
    Erriquez, Jessica
    Capellero, Sonia
    Cignetto, Simona
    Alvaro, Maria
    Ciamporcero, Eric
    Di Renzo, Maria Flavia
    Perera, Timothy
    Valabrega, Giorgio
    Olivero, Martina
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (10)
  • [32] PARP inhibitors - current status and the walk towards early breast cancer
    Glendenning, Jennifer
    Tutt, Andrew
    BREAST, 2011, 20 : S12 - S19
  • [33] Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent disease
    Dal Molin, Graziela Z.
    Westin, Shannon N.
    Coleman, Robert L.
    FUTURE ONCOLOGY, 2018, 14 (30) : 3101 - 3110
  • [34] The role of PARP inhibitors in ovarian cancer: therapeutic mechanisms and clinical data
    Song, Moo-Kon
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2021, 42 (02) : 199 - 206
  • [35] Deep exploration of PARP inhibitors in breast cancer: monotherapy and combination therapy
    Chen, Zheling
    Wang, Xiao
    Li, Xiao
    Zhou, Yucheng
    Chen, Ke
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2021, 49 (02)
  • [36] PARP Inhibitors in BRCA Gene-Mutated Ovarian Cancer and Beyond
    Banerjee, Susana
    Kaye, Stan
    CURRENT ONCOLOGY REPORTS, 2011, 13 (06) : 442 - 449
  • [37] Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status
    Keung, Man Yee
    Wu, Yanyuan
    Badar, Francesca
    Vadgama, Jaydutt V.
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (04)
  • [38] A snapshot of chemoresistance to PARP inhibitors
    Chiarugi, Alberto
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2012, 33 (01) : 42 - 48
  • [39] PARP-ish: Gaps in Molecular Understanding and Clinical Trials Targeting PARP Exacerbate Racial Disparities in Prostate Cancer
    Cunningham, Moriah L.
    Schiewer, Matthew J.
    CANCER RESEARCH, 2024, 84 (13) : 2049 - 2059
  • [40] Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer
    Taza, Fadi
    Holler, Albert E.
    Fu, Wei
    Wang, Hao
    Adra, Nabil
    Albany, Costantine
    Ashkar, Ryan
    Cheng, Heather H.
    Sokolova, Alexandra O.
    Agarwal, Neeraj
    Kessel, Adam
    Bryce, Alan
    Nafissi, Nellie
    Barata, Pedro
    Sartor, A. Oliver
    Bastos, Diogo
    Smaletz, Oren
    Berchuck, Jacob E.
    Taplin, Mary-Ellen
    Aggarwal, Rahul
    Sternberg, Cora N.
    Vlachostergios, Panagiotis J.
    Alva, Ajjai S.
    Su, Christopher
    Marshall, Catherine H.
    Antonarakis, Emmanuel S.
    JCO PRECISION ONCOLOGY, 2021, 5 : 1200 - 1220
12345